Preclinical studies in cell cultures and animal models have shown encouraging results, suggesting that MDM2 inhibitors may be effective for a specific group of GBM patients who have a wild-type (non-mutated) TP53 gene [45]. Here, MDM2 is linked to glioblastoma.